What model did the 2021 study use?

Early-life fluvoxamine exposure in rats, which perturbs serotonergic development and produces measurable behavioural and neurochemical differences.

Why induce a disturbance first?

It gives a defined thing to act against and a defined expected direction — a more demanding test than an open-ended behavioural screen.

Does 'attenuated' mean reversed?

No. It means the measured alterations were smaller in treated animals than untreated ones, in that model.

Semax (ACTH Fragment Peptide)

What the Animal Behavioural Work Reports

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Glazova and colleagues reported in Neuropeptides in 2021 that Semax attenuated behavioural and neurochemical alterations following early-life fluvoxamine exposure in rats — a model in which a disturbance is induced first and the compound tested against it.

Key facts

Study: Glazova 2021 (PMID 33418449)
Journal: Neuropeptides, April 2021
Species: Rats
Model: Early-life fluvoxamine exposure
Measured: Behavioural and neurochemical outcomes
Design type: Induced disturbance, then intervention

What the model does

Fluvoxamine is a selective serotonin reuptake inhibitor, and exposure during early development perturbs serotonergic system maturation in ways that produce measurable behavioural and neurochemical differences later. The model creates a defined disturbance rather than observing a naturally occurring one.

Why an induced-disturbance design is stronger than it looks

Testing whether a compound changes behaviour in healthy animals asks a vague question, since there may be nothing to change. Inducing a specific, characterised alteration first gives a defined thing to act against and a defined direction of expected effect. It is a more demanding test than an open-ended behavioural screen.

Research material referenced

Semax 10mg — third-party HPLC tested

View — £24.99

Why measuring neurochemistry alongside behaviour matters

Behaviour alone shows that something differs; neurochemistry indicates where. Reporting both allows a behavioural change to be connected to a biochemical one rather than left as an unexplained observation, and disagreement between the two levels is itself informative.

What attenuated means and does not mean

That the measured alterations were smaller in treated animals than in untreated ones. It does not mean they were abolished, nor that the underlying process was reversed. Attenuation is a quantitative statement about a difference between groups in one model.

The limits of the design

A developmental perturbation in rats is not a model of any human condition, and it was not built to be one. It is a tool for asking whether a compound can counteract a specific induced change. Extending that to a claim about people requires evidence of an entirely different kind, which does not exist here.

What is not claimed

Anything about behaviour, cognition or neurochemistry in any person. Semax holds no marketing authorisation from the MHRA, EMA or FDA, and material supplied here is for laboratory research only.

Extended research context

The Semax (ACTH Fragment Peptide) deep dive

Deep dive: what the Pro-Gly-Pro extension actually accomplishes

Semax is built from a four-residue fragment of ACTH with Pro-Gly-Pro appended, and that appendix does two separate jobs at once. Proline is the only proteinogenic amino acid whose side chain bonds back to its own backbone nitrogen, forming a ring that removes the amide hydrogen and locks rotation. Proteolytic enzymes generally need an extended, rotatable backbone at their active site, so bonds near proline are poor substrates for most of them — which is why proline-rich motifs recur throughout stabilised peptide design. The second job is subtractive: Pro-Gly-Pro occupies the positions where ACTH carries Arg-Trp-Gly, and those are the residues contributing to the parent hormone's adrenal-stimulating activity. One substitution therefore buys protease resistance and removes an unwanted pharmacology, which is unusually economical design.

Deep dive: the naming point worth getting right

Semax is near-universally described as an ACTH(4-10) analogue, and peer-reviewed paper titles use that phrase. Structurally it is not quite that. ACTH residues 4 to 10 are Met-Glu-His-Phe-Arg-Trp-Gly; Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues match and the last three are wholly different — replacement rather than modification. PubChem, indexing by structure rather than design lineage, records it as ACTH(4-7) plus Pro-Gly-Pro. Neither name is wrong, but the loose one obscures the fact that the substituted segment is precisely the functionally consequential part.

Deep dive: reading an unevenly distributed evidence base

Semax's roughly 231 indexed records split along an unusual line. Mechanistic work — BDNF and trkB expression in rat hippocampus, transcriptomics in focal cerebral ischaemia, neurotrophin dynamics across brain regions — appears in international journals in English and can be assessed directly. Clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry, indexed by translated title and often without accessible English full text, much of it predating current standards for pre-registration and reporting. The honest position is that this is evidence which is difficult to verify independently, which is a different thing from evidence that is absent, and a different thing again from evidence that is established.

Research applications

▸Neurotrophin expression research (BDNF, NGF, TrkB, TrkA)
▸Neuroprotection and cerebral ischaemia models
▸Study of proline-stabilised peptide design
▸Comparative work on ACTH fragments without steroidogenic activity
▸Transcriptomic profiling in rodent brain models

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the degradation route (+16 Da; only one Met, so not +32)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check whether a certificate reports net peptide content or gross salt weight

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Semax as ACTH(4-10) without qualification

Fix: It shares only residues 4-7; Pro-Gly-Pro replaces Arg-Trp-Gly, and that replacement is the design's whole point.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Semax has never been assessed by the MHRA, EMA or FDA.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The studies measured gene and protein expression in rats. Expression is upstream of function and upstream again of any clinical claim.

✗ Assuming a named receptor exists

Fix: No primary receptor has been definitively established; the literature characterises downstream effects more confidently than the initiating event.

✗ Expecting ACTH-like adrenal effects

Fix: Semax does not stimulate adrenal steroidogenesis — the responsible residues were substituted out.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What model did the 2021 study use?: Early-life fluvoxamine exposure in rats, which perturbs serotonergic development and produces measurable behavioural and neurochemical differences.
Why induce a disturbance first?: It gives a defined thing to act against and a defined expected direction — a more demanding test than an open-ended behavioural screen.
Does 'attenuated' mean reversed?: No. It means the measured alterations were smaller in treated animals than untreated ones, in that model.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Semax (ACTH Fragment Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum